Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations,
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …

Non-alcoholic fatty liver disease (NAFLD) has emerged pandemically across the globe and
particularly affects patients with obesity and type 2 diabetes. NAFLD is a complex systemic …

The liver is the sixth most common site of primary cancer in humans, and generally arises in
a background of cirrhosis and inflammation. Moreover, the liver is frequently colonized by …

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and is
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …

Nonalcoholic fatty liver disease (NAFLD), including its more severe manifestation,
nonalcoholic steatohepatitis (NASH), has a global prevalence of 20–25% and is a major …

Chronic liver diseases such as nonalcoholic fatty liver disease (NAFLD) or viral hepatitis are
characterized by persistent inflammation and subsequent liver fibrosis. Liver fibrosis critically …

The liver carries a remarkable ability to regenerate rapidly after acute zonal damage. Single-
cell approaches are necessary to study this process, given the spatial heterogeneity of liver …

Macrophages have diverse phenotypes and functions due to differences in their origin,
location and pathophysiological context. Although their main role in the liver has been …

Successful development of treatments for non-alcoholic fatty liver disease (NAFLD) and its
progressive form, non-alcoholic steatohepatitis (NASH) has been challenging. Because …

Fibrosis, or tissue scarring, develops as a pathological deviation from the physiological
wound healing response and can occur in various organs such as the heart, lung, liver …